Is XOMA or XTLB more undervalued in 2026?

CirclFi compares XOMA Royalty Corporation (XOMA) and XTL Biopharmaceuticals Ltd. (XTLB) using 13 institutional-grade valuation models. XOMA has a Quality of Company score of 8.2/10 while XTLB scores 1.7/10.

Which is a better buy — XOMA or XTLB?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do XOMA and XTLB valuations compare?

XOMA at $41.70 and XTLB at $2.46 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

XOMA vs XTLB Valuation Comparison 2026 — Intrinsic Value Analysis

XOMA

Biotechnology

XOMA Royalty Corporation

Quality

8.2

out of 10

Value Trap

SAFE

Price

$41.70

Last close

Models

13/13

Active

XTLB

Biotechnology

XTL Biopharmaceuticals Ltd.

Quality

1.7

out of 10

Value Trap

—

Price

$2.46

Last close

Models

6/13

Active

Model-by-Model Comparison

Model	Type	XOMA Fair Value	XOMA Upside	XTLB Fair Value	XTLB Upside
Bayesian DCF	Intrinsic	$9.87	-76.4%	$0.65	-73.5%
Earnings Power Value	Intrinsic	$2.83	-93.2%	—	—
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$27.28	-34.6%	$0.72	-71.6%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for XOMA vs XTLB — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

XOMA vs XTLB — Which Stock Is More Undervalued?

XOMA scores higher with a 8.2/10 quality rating vs XTLB's 1.7/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing XOMA Royalty Corporation (XOMA) and XTL Biopharmaceuticals Ltd. (XTLB) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

XOMA currently trades at $41.70 with a QOC of 8.2/10, while XTLB trades at $2.46 with a QOC of 1.7/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).